chevron_left Categories

Other related webinars

Essential Biosimilars Perspectives for Indian Ph...

Monday, 29th November, 2010
Time : 02:00 PM IST | 09:30 AM CET

Essential Biosimilars Perspectives for American ...

Thursday, 10th February, 2011
Time : 02:00 PM EST | 11:00 AM PST

Vital Perspectives on Monoclonal Antibody (mAB) ...

Monday, 18th April, 2011
Time : 02:00 PM | 11:00 AM

Essential Regulatory Perspectives and Best Clini...

Thursday, 15th September, 2011
Time : 02:00 PM IST | 09:30 AM CET

The strategic importance and key success factors...

Friday, 4th November, 2011
Time : 02:00 PM | 11:00 AM

Unwanted Immunogenicity of Biosimilars or follow...

Friday, 18th November, 2011
Time : 02:00 PM | 11:00 AM

A Glimpse of the Future - US Biosimilars Litigat...

Thursday, 15th December, 2011
Time : 02:00 PM | 11:00 AM

European approval of Biosimilar products – wha...

Thursday, 22nd December, 2011
Time : 02:00 PM EST | 11:00 AM PST

Progress report on Biosimilars including World...

Friday, 17th February, 2012
Time : 02:00 PM EST | 11:00 AM PST

Interpretation & insight into the FDA draft guid...

Friday, 2nd March, 2012
Time : 02:00 PM EST | 11:00 AM PST

FDA’s Current Thinking on Regulatory Path of B...

Friday, 16th March, 2012
Time : 02:00 PM EST | 11:00 AM PST

Comparing and contrasting FDA BIOSIMILARS guidan...

Friday, 27th April, 2012
Time : 02:00 PM EST | 11:00 AM PST

An overview of the newly released final 2012 EU ...

Wednesday, 25th July, 2012
Time : 02:00 PM EST | 11:00 AM PST

A EU/US Regulatory and Technical Practical Persp...

Friday, 31st August, 2012
Time : 02:00 PM EST | 11:00 AM PST

Assessing the Global Biosimilar Market

Friday, 5th October, 2012
Time : 02:00 PM EST | 11:00 AM PST

Harmonization in Biosimilars: EU and FDA Accepta...

Tuesday, 23rd October, 2012
Time : 02:00 PM EST | 11:00 AM PST

Scientific and Regulatory Issues in the Demonstr...

Friday, 14th December, 2012
Time : 02:00 PM EST | 11:00 AM PST

Biologics in a World with Biosimilars

Wednesday, 26th June, 2013
Time : 02:00 PM EST | 11:00 AM PST

Exploring latest FDA/EMA concepts of US-EU compa...

Friday, 15th November, 2013
Time : 02:00 PM EST | 11:00 AM PST

Executive Update of the US/EU status and opportu...

Wednesday, 27th May, 2015
Time : 02:00 PM EST | 11:00 AM PST

Biosimilar Orphan Drugs: The Next Regulatory Cha...

Friday, 21st October, 2016
Time : 01:00 PM EDT | 10:00 AM PDT

Unique executive perspectives into biologics and...

Friday, 25th November, 2016
Time : 02:00 PM IST | 09:30 AM BST

Biosimilars: Key factors for successful uptake i...

Friday, 3rd February, 2017
Time : 01:00 PM EST | 10:00 AM PST

Biosimilars Advances in the Approvals of Biosimi...

Thursday, 7th September, 2017
Time : 01:00 PM EST | 10:00 AM PST

FDA - Important Aspects to Consider When Determi...

Friday, 20th October, 2017
Time : 01:00 PM EST | 10:30 AM PST

Pitfalls in the Analytical Characterization of B...

Friday, 22nd December, 2017
Time : 01:00 PM EST | 10:30 AM PST

Understanding Bioavailability And Bioequivalence...

Wednesday, 28th March, 2018
Time : 01:00 PM EST | 11:30 AM BST

FDA Interchangeability Requirements for Biosimil...

Thursday, 19th April, 2018
Time : 01:00 PM EST | 10:00 AM PST

Executive insights into the FDA "Purple Book" Cl...

Friday, 17th July, 2020
Time : 01:00 PM EST | 11:30 AM BST

Evaluating the pathway for registration of Biosi...

Friday, 23rd September, 2022
Time : 01:00 PM EST | 10:00 AM PST

Recorded Webinar

Understanding Bioavailability And Bioequivalence Studies Required for INDs, NDAs and Post-Approval Filings

timelapse 60 Min with 15 Min QnA of Q and A

Note:

This webinar occured in the past
Along with recorded webinar, copy of presentation slides will be shared
Recorded Webinar can be played unlimited times

Speaker/Presenter

Short Abstract

Bioavailability (BA) and Bioequivalence(BE) Studies submitted for INDs, NDAs and post-approval filings will be discussed during this webinar. BE studies are primarily associated with establishing that a generic product filed in an ANDA is the “same” as the innovator product. However, BE studies, though done for a different purpose, are very often necessary to support INDs, NDAs, and post-approval filings. Information generated from such studies influence the overall clinical development plan and product labeling.
Areas Covered in the Webinar:

  • All relevant regulatory requirements for establishing the necessary BA and/or BE studies for INDs, NDAs and supplements to NDAs.
  • Differences between BE studies for ANDAs and studies required for INDs, NDAs and post-approval filings.
  • Determine the overall clinical development plan and labeling of the product.
  • Types of BA and BE studies, including for INDs, as well as pivotal BE studies required to bridge the to-be-marketed formulation


Apply for this webinar

Content Disclaimer

Contents in our website are from external websites. Links to and content from external website are provided for the convenience of users. Biopractice.com takes no responsibility for the content of such links and websites.

//